Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.
暂无分享,去创建一个
G. Remuzzi | J. Wetzels | P. Ruggenenti | A. Perna | J. V. D. van den Brand | B. Ruggiero | J. Hofstra | Antonietta Chianca | J. van den Brand
[1] D. Cattran,et al. Membranous Nephropathy: Quantifying Remission Duration on Outcome. , 2017, Journal of the American Society of Nephrology : JASN.
[2] D. Furst,et al. Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years , 2015, The Journal of Rheumatology.
[3] J. Wetzels,et al. A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus–Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study , 2015, Clinical kidney journal.
[4] B. Rovin,et al. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). , 2015, Nephron.
[5] G. Remuzzi,et al. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.
[6] Javier Zamora,et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. , 2014, The Cochrane database of systematic reviews.
[7] P. Saxena,et al. Clinical Trials: Changing Regulations in India , 2014, Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine.
[8] J. Wetzels,et al. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy. , 2014, Clinical journal of the American Society of Nephrology : CJASN.
[9] C. Ponticelli,et al. Glomerular diseases: membranous nephropathy--a modern view. , 2014, Clinical journal of the American Society of Nephrology : CJASN.
[10] J. Wetzels,et al. Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. , 2014, Journal of the American Society of Nephrology : JASN.
[11] C. Peh. Commentary on the KDIGO Clinical Practice Guideline for Glomerulonephritis , 2013, Nephrology.
[12] G. Remuzzi,et al. Rituximab in idiopathic membranous nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.
[13] Jai Radhakrishnan,et al. Notice , 2012, Kidney International Supplements.
[14] J. Wetzels,et al. Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[15] David M. Beck,et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.
[16] P. Höglund,et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials , 2011, Annals of the rheumatic diseases.
[17] Jan P Vandenbroucke,et al. Observational Research, Randomised Trials, and Two Views of Medical Science , 2008, PLoS medicine.
[18] G. Remuzzi,et al. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. , 2007, Clinical journal of the American Society of Nephrology : CJASN.
[19] M. Vervloet,et al. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[20] K. Sud,et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. , 2007, Journal of the American Society of Nephrology : JASN.
[21] W. Ray,et al. Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.
[22] G. Remuzzi,et al. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes , 1998, BMJ.
[23] R. Fleming. An Overview of Cyclophosphamide and Ifosfamide Pharmacology , 1997, Pharmacotherapy.
[24] F. Locatelli,et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. , 1995, Kidney international.
[25] C. Ponticelli,et al. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. , 1992, The New England journal of medicine.
[26] F. Locatelli,et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. , 1989, The New England journal of medicine.
[27] C. Ponticelli,et al. A Randomized Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous Nephropathy , 1984 .